48 related articles for article (PubMed ID: 9450578)
1. Digital ischaemia and necrosis from oxaliplatin.
Huang C; Storey L; Chaudhary U
BMJ Case Rep; 2022 Feb; 15(2):. PubMed ID: 35131793
[TBL] [Abstract][Full Text] [Related]
2. Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer.
Tsuboya A; Fujita KI; Kubota Y; Ishida H; Taki-Takemoto I; Kamei D; Iwai S; Sasaki Y
Int J Clin Oncol; 2019 Feb; 24(2):222-230. PubMed ID: 30244364
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan-induced dysarthria: an insight into its pathogenesis?
Gomez JA; Sanchez I; Ramirez JA
Gastrointest Cancer Res; 2008 Jul; 2(4):209-10. PubMed ID: 19259288
[No Abstract] [Full Text] [Related]
4. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.
Fischel JL; Rostagno P; Formento P; Dubreuil A; Etienne MC; Milano G
Br J Cancer; 2001 Feb; 84(4):579-85. PubMed ID: 11207057
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Valencak J; Raderer M; Kornek GV; Henja MH; Scheithauer W
J Natl Cancer Inst; 1998 Jan; 90(2):160. PubMed ID: 9450578
[No Abstract] [Full Text] [Related]
7. Re: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Cvitkovic E; Marty M; Wasserman E; Cuvier C; Goldwasser F; Misset JL
J Natl Cancer Inst; 1998 Jul; 90(13):1016-7. PubMed ID: 9665154
[No Abstract] [Full Text] [Related]
8. More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Dodds HM; Bishop JF; Rivory LP
J Natl Cancer Inst; 1999 Jan; 91(1):91-2. PubMed ID: 9890180
[No Abstract] [Full Text] [Related]
9. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
Lloyd Jones M; Hummel S; Bansback N; Orr B; Seymour M
Health Technol Assess; 2001; 5(25):1-128. PubMed ID: 11990245
[No Abstract] [Full Text] [Related]
10. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Fernandez FG; Ritter J; Goodwin JW; Linehan DC; Hawkins WG; Strasberg SM
J Am Coll Surg; 2005 Jun; 200(6):845-53. PubMed ID: 15922194
[TBL] [Abstract][Full Text] [Related]
11. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
